Global Phase 2b Clinical Data for CytRx’s Aldoxorubicin to be Featured at the Connective Tissue Oncology Society Annual

  Global Phase 2b Clinical Data for CytRx’s Aldoxorubicin to be Featured at
  the Connective Tissue Oncology Society Annual Meeting

  Compelling Phase 2b data selected for a poster presentation at preeminent
                              sarcoma conference

CTOS 2013

Business Wire

LOS ANGELES -- October 23, 2013

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development
company specializing in oncology, today announced that additional preliminary
data from its Phase 2b clinical trial demonstrating aldoxorubicin’s potential
advantage over doxorubicin in the treatment of soft tissue sarcoma (STS) will
be presented at the 18^th Annual Connective Tissue Oncology Society (CTOS)
Meeting on Thursday, October 31 at 4:30 p.m. Eastern time at the Sheraton New
York Times Square Hotel.

The Company previously reported that patients in the trial treated with
aldoxorubicin had an Overall Response Rate (ORR) of 22%, whereas those
administered the widely used chemotherapeutic agent doxorubicin had an ORR of
0%. The Company expects to report top-line data for the global Phase 2b
clinical trial in December 2013.

“Because CTOS draws thought leaders in the treatment of sarcoma from around
the world, it provides an ideal forum to gain awareness of this compelling
data and to acquaint the oncologists with our phase 3 study in patients with
relapsed or refractory soft tissue sarcomas,” said CytRx President and CEO
Steven A. Kriegsman. "Discoveries of new sarcoma treatments have been
relatively few, particularly when compared with treatments for breast or
prostate cancer, but the preliminary clinical results thus far drive our
optimism that aldoxorubicin can fill an important medical need in patients
with advanced soft tissue sarcoma. ”

STS is a cancer occurring in muscle, fat, blood vessels, tendons, fibrous
tissues and connective tissue, and can arise anywhere in the body at any age.
There are more than 30 types of STS, and according to the American Cancer
Society more than 10,500 new cases are diagnosed each year in the U.S.

In addition to the Phase 2b trial for STS, the Company has received acceptance
from the U.S. Food and Drug Administration (FDA) for a protocol to conduct a
Phase 2 clinical trial with aldoxorubicin in glioblastoma, a
difficult-to-treat and deadly brain cancer, and also plans to conduct a Phase
2 clinical trial in HIV-related Kaposi’s sarcoma.

About Aldoxorubicin

The widely used chemotherapeutic agent doxorubicin is delivered systemically
and is highly toxic, which limits its dose to a level below its maximum
therapeutic benefit. Doxorubicin also is associated with many side effects,
especially the potential for damage to heart muscle at cumulative doses
greater than 500 mg/m^2. Aldoxorubicin combines doxorubicin with a novel
single-molecule linker that binds directly and specifically to circulating
albumin, the most plentiful protein in the bloodstream. Protein-hungry tumors
concentrate albumin, thus increasing the delivery of the linker molecule with
the attached doxorubicin to tumor sites. In the acidic environment of the
tumor, but not the neutral environment of healthy tissues, doxorubicin is
released. This allows for greater doses of doxorubicin to be administered
while reducing its toxic side effects. In studies thus far there has been no
evidence of clinically significant effects of aldoxorubicin on heart muscle,
even at cumulative doses of drug well in excess of 2 g/m^2.

About the Connective Tissue Oncology Society

Formed in 1995 and incorporated in 1997, the Connective Tissue Oncology
Society (CTOS) is an international group comprised of physicians and
scientists with a primary interest in the tumors of connective tissues. The
goal of the society is to advance the care of patients with connective tissue
tumors and to increase knowledge of all aspects of the biology of these
tumors, including basic and clinical research.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company
specializing in oncology. CytRx currently is focused on the clinical
development of aldoxorubicin (formerly known as INNO-206), its improved
version of the widely used chemotherapeutic agent doxorubicin. CytRx is
conducting a global Phase 2b clinical trial with aldoxorubicin as a treatment
for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial
primarily in the same indication and a Phase 1b study of aldoxorubicin in
combination with doxorubicin in patients with advanced solid tumors, and has
completed a Phase 1b pharmacokinetics clinical trial in patients with
metastatic solid tumors. CytRx plans to initiate under a special protocol
assessment a potential pivotal Phase 3 global trial with aldoxorubicin as a
therapy for patients with soft tissue sarcomas whose tumors have progressed
following treatment with chemotherapy. CytRx also is initiating Phase 2
clinical trials with aldoxorubicin in patients with late-stage glioblastoma
(brain cancer) and AIDS-related Kaposi’s sarcoma. CytRx plans to expand its
pipeline of oncology candidates based on a linker platform technology that can
be utilized with multiple chemotherapeutic agents and may allow for greater
concentration of drug at tumor sites. CytRx also has rights to two additional
drug candidates, tamibarotene and bafetinib. CytRx completed its evaluation of
bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic
lymphocytic leukemia (B-CLL), and plans to seek a partner for further
development of bafetinib. For more information about CytRx Corporation, visit
www.cytrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements involve risks and uncertainties that could cause actual events or
results to differ materially from the events or results described in the
forward-looking statements, including risks relating to the outcome, timing
and results of CytRx's clinical trials, the risk that any future human testing
of aldoxorubicin, including the conclusion of the Phase 2b clinical testing of
aldoxorubicin as a first-line treatment in patients with metastatic, locally
advanced or unresectable soft tissue sarcomas who have not been previously
treated with any chemotherapy, might not produce objective response results
similar to the preliminary data described in this press release, or might not
correlate with the trial’s primary endpoint of progression-free survival,
risks related to CytRx's ability to manufacture its drug candidates in a
timely fashion, cost-effectively or in commercial quantities in compliance
with stringent regulatory requirements, risks related to CytRx's need for
additional capital or strategic partnerships to fund its ongoing working
capital needs and development efforts, including the Phase 3 clinical
development of aldoxorubicin, and the risks and uncertainties described in the
most recent annual and quarterly reports filed by CytRx with the Securities
and Exchange Commission and current reports filed since the date of CytRx's
most recent annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first published.
CytRx undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

Contact:

Investor Relations Contacts:
CytRx Corporation
David J. Haen
Vice President, Business Development
310-826-5648, x304
dhaen@cytrx.com
or
Legend Securities, Inc.
John M. Columbia
718-233-2677
jcolumbia@legendsecurities.com
 
Press spacebar to pause and continue. Press esc to stop.